Novartis

Granite Bio is a biotechnology company that specializes in the development of novel monoclonal antibodies aimed at treating inflammatory, autoimmune, and fibrotic disorders. The company's primary focus is on creating therapeutic antibodies that deplete pathogenic cells and selectively target key biological pathways associated with these diseases. By advancing innovative antibody treatments, Granite Bio aims to contribute significantly to the fields of biotechnology and pharmaceuticals, addressing critical needs in the life sciences sector.

Anthos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on advancing therapies for cardiovascular and metabolic diseases. Founded in 2018, the company specializes in developing innovative treatments that target Factor XI and XIa, critical components of the intrinsic coagulation pathway. Its lead product, MAA868, is an anti-thrombotic investigational therapy designed to prevent thrombotic events while minimizing the risk of bleeding. By offering a long-acting treatment paradigm, Anthos Therapeutics aims to provide significant advantages over conventional standards of care, ultimately enhancing patient outcomes in cardiovascular health.

Rhygaze is a biotechnology company focused on developing innovative gene therapies aimed at restoring vision in individuals affected by blindness-related diseases. The company’s therapy utilizes advanced technology to deliver a light-sensor gene directly to cone cells that have lost their light sensitivity. By repairing these cells' ability to detect light, Rhygaze seeks to enable effective vision restoration for patients. Through its specialized approach, the company aims to make significant contributions to the healthcare industry and improve the quality of life for those facing vision loss.

Alesta Therapeutics is a biotechnology company dedicated to developing innovative therapies for cancer treatment. The company focuses on small molecule programs that target synthetic lethal metabolic dependencies within cancer cells. By addressing control mechanisms involved in chronic stress response pathways critical for cancer cell survival, Alesta Therapeutics aims to create therapeutic approaches that can effectively inhibit pathways essential for cancer growth. This targeted strategy seeks to offer new treatment options for patients, ultimately enhancing cancer care by translating novel scientific insights into practical medical solutions.

Aeonaux Capital is a WealthTech company based in India, specializing in quantitative investment strategies for retail and high net worth individuals. The firm leverages artificial intelligence and machine learning to create low-volatility, high-return portfolios across various asset classes, including equity, derivatives, and fixed income. Aeonaux's platform offers real-time data analytics and a systematic investment process, enabling users to manage their portfolios effectively. Backed by international investors, the company combines technology and finance to provide data-driven portfolio management solutions.

Citryll is a private pharmaceutical company based in Oss, The Netherlands, established in 2015. The company specializes in the development of pharmaceutical drugs aimed at treating autoimmune and other human diseases. Citryll's innovative approach focuses on the formation, function, and clearance of neutrophil extracellular traps (NETs) that are associated with the protein citrullination pathway, which is catalyzed by Peptidylarginine Deiminase (PAD) enzymes. This research and development are instrumental in providing treatment options for various conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

Kate Therapeutics is a biotechnology company specializing in the development of adeno-associated virus (AAV)-based gene therapies aimed at treating genetically defined muscle and heart diseases. The company employs innovative technology platforms that enhance tissue-specific delivery and gene regulation, effectively addressing the limitations of existing gene therapies. By utilizing novel capsids, Kate Therapeutics achieves superior muscle transduction and liver de-targeting compared to naturally occurring serotypes, facilitating more effective tissue transduction at significantly lower viral doses. This advancement helps to overcome major challenges in muscle gene delivery, ultimately improving treatment outcomes for patients with these specific conditions.

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.

ONL Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies to protect and improve vision in patients with retinal diseases. Established in 2006, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway, offering potential protection for photoreceptors. Its drug programs are designed to address serious, vision-threatening conditions, including retinal detachment, ultimately aiming to enhance surgical outcomes and patient quality of life through the use of small-molecule peptides.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Borealis Biosciences is a discovery-stage biotechnology company focused on developing next-generation RNA-based therapies, particularly targeting kidney diseases. The company specializes in molecular and cellular biology, chemistry, and analytical capabilities, utilizing these strengths to identify and map target opportunities within specific patient subsets affected by kidney conditions. Borealis aims to enhance the delivery mechanisms of RNA medicines to distinct cell types, thereby addressing significant unmet medical needs in the treatment of kidney diseases.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Rhygaze is a biotechnology company focused on developing innovative gene therapies aimed at restoring vision in individuals affected by blindness-related diseases. The company’s therapy utilizes advanced technology to deliver a light-sensor gene directly to cone cells that have lost their light sensitivity. By repairing these cells' ability to detect light, Rhygaze seeks to enable effective vision restoration for patients. Through its specialized approach, the company aims to make significant contributions to the healthcare industry and improve the quality of life for those facing vision loss.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Mariana Oncology is a biotechnology company focused on developing innovative radiopharmaceuticals aimed at targeting cancer cells with radioactive drugs. The company employs a multidisciplinary approach that includes ligand discovery, radiochemistry, radiobiology, and translational and clinical research in oncology. By building a diverse pipeline of treatments for various solid tumor types, Mariana Oncology seeks to enhance the efficacy of radio medicines in cancer therapy, ultimately aiding medical professionals in their efforts to improve patient outcomes.

FundaMental Pharma is a neuroscience company focused on developing innovative therapies to address neurological diseases. The company is engaged in the creation of neuroprotective molecular spacers aimed at preventing neurodegeneration in the brain. By utilizing peptides and gene therapy techniques, FundaMental Pharma works on diagnosing genetic polymorphisms and specializes in a new class of drugs designed to combat conditions that are currently untreatable. Their research and development efforts are concentrated on providing pharmacological solutions for patients suffering from challenging neurological conditions. With a portfolio positioned at the preclinical stage, FundaMental Pharma is dedicated to advancing treatments that could potentially improve the lives of individuals affected by these disorders.

Capstan Therapeutics is a biotechnology company focused on advancing precision in vivo cell engineering to create therapeutics for various disease categories that have unmet or underserved clinical needs. The company specializes in expanding the therapeutic potential of RNA-based therapies through proprietary targeted delivery systems. Their platform utilizes targeted lipid nanoparticles to enhance off-the-shelf immunotherapies, providing tight control over dosage and activity of engineered cells. This approach aims to develop transformative products for conditions such as oncology, fibrosis, and inflammation-related diseases.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Aravax is an early-stage biotechnology company based in Melbourne, Australia, dedicated to developing a safe and effective treatment for peanut allergy. Founded in May 2015, the company emerged from the acquisition of intellectual property developed by Alfred Health and Monash University. Aravax's innovative approach involves proprietary technology that aims to reset the immune system, allowing patients to tolerate peanuts without experiencing allergic reactions during treatment. The company's focus is on creating vaccines that mitigate the risk of life-threatening responses to peanuts, providing a potential solution for individuals suffering from peanut allergies.

Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in the discovery and development of monoclonal antibodies aimed at treating immune pathologies and addressing significant unmet medical needs. Calypso Biotech focuses on innovative therapies for autoimmune diseases, particularly those affecting patients with severe gastrointestinal conditions such as gastric and pancreatic cancer. The company operates as a semi-virtual organization, leveraging a highly experienced management team with extensive expertise in drug development and a robust scientific network to enhance value for its investors through a portfolio of proprietary antibody candidates.

SanReno Therapeutics is a biotechnology company that specializes in the development, manufacturing, and commercialization of therapies for kidney diseases and related conditions. Operating primarily in the People’s Republic of China, Hong Kong, Macau, Taiwan, and Singapore, the company is dedicated to advancing research and development in this therapeutic area. Formed as a joint venture between Chinook Therapeutics, Frazier Healthcare Partners, and Pivotal bioVenture Partners China, SanReno Therapeutics aims to create innovative solutions that enhance the quality of life for patients suffering from kidney-related ailments.

Yseop is an artificial intelligence company specializing in natural language generation software tailored for various industries, including finance and life sciences. Its platform automates the creation of intelligent and non-repetitive text in multiple languages, enabling businesses to enhance efficiency and customer engagement. By utilizing a patented technology, Yseop streamlines tasks such as lead generation, report writing, and personalized proposals, allowing sales and marketing teams to focus more on customer interactions rather than administrative duties. This automation not only reduces operational costs but also improves the overall effectiveness of customer relations. Yseop offers its services through a Software as a Service (SaaS) model or as an annual license that can be hosted on a client’s servers, ensuring flexibility for its users. The software supports text generation in English, German, Dutch, French, Spanish, and Japanese, thereby catering to a global clientele.

AstronauTx is a biotechnology company focused on developing innovative treatments for Alzheimer's disease and other neurodegenerative conditions. The company specializes in restoring the normal function of astrocytes, which are crucial for supporting neuronal activity and maintaining brain health. In healthy individuals, astrocytes play a vital role in metabolism and the integrity of the blood-brain barrier; however, in neurodegenerative diseases, their dysfunction can contribute to neurotoxicity. By targeting these processes, AstronauTx aims to enable healthcare professionals to more effectively address the challenges posed by dementias, ultimately improving patient outcomes.

Northern Yiheng is a producer of composite insulation materials made of semiconductor graphite fiber.

Hyku is a biotechnology company focused on developing small molecule therapeutics that utilize precise covalent targeting to address disease-causing proteins. The company employs a unique platform to identify molecules that covalently bind to non-cysteine amino acids, facilitating the creation of innovative medicines. Hyku's approach aims to tackle significant challenges in the treatment of various diseases, including issues related to selectivity, druggability, and resistance. By advancing the science of covalent medicines, Hyku strives to enhance treatment options and improve patient outcomes.

Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

DTx Pharma, LLC is a biotechnology company headquartered in San Diego, California, specializing in the development and commercialization of fatty acid-conjugated peptide therapeutics. Founded in 2017, the company focuses on delivering RNA-based medicines to treat patients with rare and chronic diseases, including retinitis pigmentosa, Duchenne muscular dystrophy, and various central nervous system disorders. DTx Pharma's innovative delivery technology addresses challenges faced by previous-generation platforms, such as poor pharmacokinetics and limited cellular uptake, thereby enhancing the efficiency of nucleic acid drug delivery across diverse tissues and cell types. The company aims to establish RNA therapeutics as a leading option for personalized treatment in multiple therapeutic areas.

Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

Medtech Africa provides a medical platform (Forcardio) that enables caregivers to use health monitoring to manage and improve the care of their patients. We provide easy access to continuous medical care for cardiovascular disease management and care in emerging markets. We provide cost-effective and simplified tools that provide proactive, personalized, and timely information about people living with chronic conditions such as diabetes, hypertension, and heart failure.

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company based in Seattle, Washington, that specializes in the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead program is atrasentan, an investigational endothelin receptor antagonist currently prepared for Phase III trials targeting IgA nephropathy and other primary glomerular diseases. In addition to atrasentan, Chinook is developing BION-1301, an investigational anti-APRIL monoclonal antibody evaluated in a Phase Ib trial for IgA nephropathy, and CHK-336, a preclinical candidate aimed at treating an undisclosed ultra-orphan kidney disease. Chinook Therapeutics is also engaged in research programs addressing other rare and severe chronic kidney conditions, including polycystic kidney disease.

RxLightning is a digital platform that focuses on improving access to specialty medications for patients. By automating and streamlining the traditionally complex manual enrollment process, RxLightning facilitates faster initiation of therapy across various therapeutic areas, including addiction medicine, cardiology, endocrinology, and dermatology. The platform enhances communication between healthcare providers and reduces the burden of paperwork, thereby accelerating the time it takes for patients to access necessary treatments.

Yuweitek is a company that excels in the independent research and development of core technologies focused on the integration of software and hardware applications. Specializing in Beidou satellite positioning, vehicle communication, driving data recording, intelligent video algorithms, and connected vehicle technology, Yuweitek aims to enhance car safety monitoring and remote vehicle management. The company offers a diverse range of products, including energy vehicle terminals, satellite positioning wireless terminals, multimedia video monitoring devices, and high-definition cameras, categorized into nine product series. In addition to its hardware offerings, Yuweitek provides industry platform management software systems, delivering comprehensive solutions to meet client needs in the evolving automotive landscape.

Patientory Inc., established in 2015 and headquartered in Atlanta, Georgia, specializes in developing a personal healthcare solution named Patientory. This platform enables individuals to securely manage their medical records, monitor chronic illnesses, and access relevant health information. Simultaneously, it facilitates healthcare providers' connection with patients for support and care coordination. By empowering users to control their health data and incentivizing healthier lifestyles through personalized rewards, Patientory aims to streamline interactions between healthcare stakeholders and patients while reducing care costs.

Flare Therapeutics is a biotechnology company dedicated to developing small molecule medicines through a novel approach to understanding transcription factors. By identifying 'switch sites,' which are druggable regions crucial for regulating transcription factors, Flare aims to target mutations that lead to various diseases. The company has rapidly advanced its drug discovery efforts, creating an emerging pipeline of programs initially focused on precision oncology. Additionally, Flare's innovative platform holds promise for addressing conditions in neurology, rare genetic disorders, immunology, and inflammation, ultimately enabling medical professionals to transform treatment strategies for patients.

Mediar Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. It specializes in developing antibody-based therapeutics targeting key fibrotic mediator proteins involved in fibrosis, aiming to halt and potentially reverse this condition in chronically damaged organs. The company operates at the pre-clinical stage.

Oculis Holding AG is a global biopharmaceutical company focused on advancing eye care and preserving vision. The company has developed a novel drug delivery platform that enhances the absorption of therapeutics to both the anterior and posterior segments of the eye. This innovative approach enables the treatment of posterior eye diseases, such as diabetic macular edema, through a simple topical application, thus offering a non-invasive alternative to traditional methods. Oculis's product pipeline includes OCS-01, a topical treatment for diabetic macular edema; OCS-02, a topical biologic for dry eye disease; and OCS-05, a disease-modifying candidate targeting acute optic neuritis and other neuro-ophthalmic disorders, including glaucoma and diabetic retinopathy. Through its cutting-edge technologies and therapeutic candidates, Oculis aims to significantly improve patient outcomes in the field of ophthalmology.

Holmusk is a health data analytics company focused on enhancing treatment for mental health and chronic diseases. It develops a real-world evidence platform that integrates specialty behavioral health data with advanced analytics to provide evidence-based insights for treatment decisions. By leveraging artificial intelligence and data science, Holmusk accelerates research and improves patient outcomes through predictive algorithms. Its proprietary modeling platform enables clients to analyze real-world data, facilitating personalized medicine and driving data-driven approaches in healthcare. The company's mission is to expand evidence-based care for individuals managing behavioral health conditions, ultimately supporting the commercialization of new treatments.

At Docthus, we are dedicated to addressing the critical challenge of reducing variations in care and ensuring that every patient receives the best care each time. With our innovative platform, doctors can stay at the forefront of medical advancements, access live surgeries, participate in interactive webinars, and collaborate with a network of experts. By empowering doctors with up-to-date knowledge and fostering collaboration, we enable them to deliver the highest standard of care, ultimately improving patient outcomes and eliminating disparities in healthcare.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Orionis Biosciences is an early-stage biotechnology company dedicated to drug discovery and development, primarily targeting oncology and immunotherapies for diseases with significant unmet medical needs. Based in Waltham, Massachusetts, with additional research facilities in Ghent, Belgium, the company utilizes innovative technologies to create conditionally active drug modalities. Orionis employs mechanisms of molecular proximity and cooperativity to enhance drug potency and precision, leading to a diverse pipeline of drug candidates. These efforts include the development of small molecules that engage both adaptive and innate immune systems, paving the way for effective single-agent therapies for cancer and other life-threatening conditions. The company is supported by a team of experienced professionals and maintains strategic collaborations with leading research institutions, such as VIB in Belgium.

Capstan Therapeutics is a biotechnology company focused on advancing precision in vivo cell engineering to create therapeutics for various disease categories that have unmet or underserved clinical needs. The company specializes in expanding the therapeutic potential of RNA-based therapies through proprietary targeted delivery systems. Their platform utilizes targeted lipid nanoparticles to enhance off-the-shelf immunotherapies, providing tight control over dosage and activity of engineered cells. This approach aims to develop transformative products for conditions such as oncology, fibrosis, and inflammation-related diseases.

Aktis Oncology is a biotechnology company focused on the discovery and development of a new class of targeted radiopharmaceuticals aimed at treating various solid tumor cancers. The company has developed proprietary platforms to create tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered for high tumor penetration and prolonged residence time, allowing for effective tumor elimination while reducing the side effects typically associated with cancer treatments. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing treatment precision and efficacy.

Kedalion Therapeutics Inc. is an ophthalmic drug company based in Menlo Park, California, founded in 2015. The company specializes in the development and commercialization of innovative topical ophthalmic therapies for various indications. Kedalion's proprietary AcuStream platform technology enhances the delivery of topical drugs to the eye with precision, allowing for comparable therapeutic effects while reducing the required dosage by up to 80% compared to traditional eye drops. This novel, digitally connected, electromechanical delivery device addresses the need for a user-friendly option that ensures reliable and comfortable administration of ocular therapies. By improving efficiency, patient comfort, and minimizing side effects, Kedalion aims to enhance the overall experience for both patients and healthcare providers while alleviating some of the burdens on the healthcare system.

Cleerly is a healthcare company focused on transforming the management of coronary artery disease through innovative digital care pathways aimed at preventing heart attacks. By combining advanced clinical science with state-of-the-art artificial intelligence, Cleerly develops a platform that delivers actionable clinical insights for all stakeholders involved in heart care. This platform employs a non-invasive approach to analyze and characterize plaque buildup in coronary arteries, allowing healthcare providers to better identify at-risk patients and facilitate early treatment. Cleerly's data-driven solutions not only enhance the evaluation of cardiovascular disease but also aim to improve patient heart health while delivering value to the healthcare system.

Alladapt Immunotherapeutics, founded in 2018 and based in Menlo Park, California, is a privately held biopharmaceutical company dedicated to developing therapeutics for food allergy treatment. Its lead product, ADP101, is an oral immunotherapy designed to mitigate allergic reactions triggered by multiple common allergens, offering a broad-spectrum solution for patients with various food allergies.

Deciphex Limited, founded in 2017 and headquartered in Dublin, Ireland, specializes in developing digital pathology software applications that leverage artificial intelligence to enhance diagnostic workflows. The company offers two primary platforms: Diagnexia, which facilitates rapid diagnostics by connecting global subspecialty pathologists to address backlogs, and Patholytix Preclinical, designed for optimizing preclinical safety assessments in pharmaceutical research. By automating routine tasks and triaging high-volume, low-complexity samples, Deciphex enables pathologists to concentrate on more complex cases, ultimately improving productivity and patient outcomes. Through its innovative approach, Deciphex is committed to advancing healthcare delivery and therapeutic development.

Parrots Inc. is a medical devices company focused on creating innovative assistive technology platforms for individuals facing mobility and communication challenges. The company has developed Polly, a socially assistive robot designed to be a friendly companion, providing users with support in interacting with their environment. Polly operates through hands-free control methods, such as eye-tracking and various ability switches, making it accessible for a wide range of users. Parrots emphasizes five core values: Communication, with advanced AI-driven real-time interaction; Control, featuring comprehensive 360-degree computer vision; Connectivity, allowing integration with smart-home devices; Compatibility, supporting various assistive technologies; and Caregiving, aimed at enhancing user independence while alleviating the burden on caregivers. The company's technology not only facilitates communication by converting spoken words to text and tracking vital signs, but also strives to maximize the independence of those with physical challenges.

Klarah is a digital health company specializing in telehealth solutions. It operates a platform that connects patients with a network of specialist doctors and nurses, providing remote medical consultations, support, and monitoring. The company's services include wound care, wellness checks, post-hospital care, and diabetes management. Klarah's platform also offers a dashboard for accessing medical history and real-time updates on key health parameters. Notably, Klarah focuses on serving the African diaspora by providing quality healthcare to their loved ones on the continent.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Splice Bio is a biotechnology company based in Barcelona, Spain, that specializes in developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012, the company focuses on addressing the needs of patients suffering from incurable genetic diseases. Splice Bio's technology, originally developed in the Muir Lab at Princeton University, enhances the capabilities of traditional adeno-associated viruses (AAVs) by allowing for larger gene cargo delivery and targeting a broader range of tissues. This advancement aims to overcome existing limitations in gene therapy, making it a promising solution for treating complex genetic disorders. The company was formerly known as Proteodesign, S.L. before rebranding to Splice Bio in September 2020.

Koneksa Health Inc. is a healthcare data analytics company that specializes in designing and developing software solutions for pharmaceutical and biotech firms. The company’s flagship product, Koneksa Compare, facilitates the collection, monitoring, and analysis of patient-generated data to support clinical studies and regulatory claims. By integrating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires, Koneksa enhances the accuracy and breadth of data that researchers can analyze, thereby minimizing subjective biases in clinical endpoints. Additionally, the platform provides a dashboard that offers electronic clinical outcome assessments and reminders for study participants. Established in 2013 and headquartered in New York, Koneksa also maintains a presence in London, United Kingdom, and is recognized for its contributions to improving the efficiency of drug development through innovative data analysis.

ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells for the treatment of solid tumors. The company specializes in creating chimeric antigen receptor (CAR) T-cell therapies that target specific gene loss features in tumor cells, allowing for the selective destruction of cancerous tissues while preserving healthy ones. This technology aims to enhance tumor specificity, enabling the CAR-T cells to induce cytotoxicity only when engaging with tumor cells, thereby minimizing the safety risks commonly associated with existing CAR-T therapies. ImmPACT Bio's innovative approach seeks to improve treatment outcomes for cancer patients by offering a more precise and safer therapeutic option.

Shenzhen Ikas Industrial Automation Co., Ltd. specializes in providing intelligent manufacturing solutions for industries such as integrated circuit (IC) manufacturing, packaging testing, LED, and photovoltaic sectors. Founded in 2017 and based in Shenzhen, China, the company has developed an advanced industrial system modeling technology called ROPN, which integrates artificial intelligence and big data. This technology supports the creation of over 30 modular products designed for various aspects of the manufacturing process, including equipment maintenance and production scheduling. By leveraging industrial AI technologies and the core principles of the Industrial Internet of Things, IKAS aims to enhance automation, improve production efficiency, and minimize reliance on manual labor in the manufacturing ecosystem.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Anaveon AG is a biopharmaceutical company based in Bottmingen, Switzerland, founded in 2017. The company specializes in the development of biologics aimed at modulating cytokine functions to provide therapeutic benefits for patients with immune pathology. Anaveon focuses on creating next-generation IL-2-based therapeutic antibodies that selectively enhance effector T cell functions, thereby acting as effective immune adjuvants. Its compounds demonstrate substantial preclinical efficacy against cancer, both as monotherapy and in combination with other treatments. Through these advancements, Anaveon aims to transform cytokines into life-saving treatments for various diseases associated with immune system dysfunction.

Holmusk is a health data analytics company focused on enhancing treatment for mental health and chronic diseases. It develops a real-world evidence platform that integrates specialty behavioral health data with advanced analytics to provide evidence-based insights for treatment decisions. By leveraging artificial intelligence and data science, Holmusk accelerates research and improves patient outcomes through predictive algorithms. Its proprietary modeling platform enables clients to analyze real-world data, facilitating personalized medicine and driving data-driven approaches in healthcare. The company's mission is to expand evidence-based care for individuals managing behavioral health conditions, ultimately supporting the commercialization of new treatments.

Medtech Africa provides a medical platform (Forcardio) that enables caregivers to use health monitoring to manage and improve the care of their patients. We provide easy access to continuous medical care for cardiovascular disease management and care in emerging markets. We provide cost-effective and simplified tools that provide proactive, personalized, and timely information about people living with chronic conditions such as diabetes, hypertension, and heart failure.

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.

Kedalion Therapeutics Inc. is an ophthalmic drug company based in Menlo Park, California, founded in 2015. The company specializes in the development and commercialization of innovative topical ophthalmic therapies for various indications. Kedalion's proprietary AcuStream platform technology enhances the delivery of topical drugs to the eye with precision, allowing for comparable therapeutic effects while reducing the required dosage by up to 80% compared to traditional eye drops. This novel, digitally connected, electromechanical delivery device addresses the need for a user-friendly option that ensures reliable and comfortable administration of ocular therapies. By improving efficiency, patient comfort, and minimizing side effects, Kedalion aims to enhance the overall experience for both patients and healthcare providers while alleviating some of the burdens on the healthcare system.

Mekonos Inc. is a biotechnology company founded in 2017 and based in San Francisco, California, specializing in the design, development, and production of gene and cell therapies. The company has created a proprietary cell-engineering platform that utilizes a silicon chip automated architecture to advance the field of genome editing. This innovative system-on-a-chip technology allows for the precise control of individual nanoneedles to inject single cells in a parallel architecture, enabling the industrial-scale production of engineered therapies for a range of genetic diseases, including cancers. Mekonos aims to provide healthcare providers with a reliable and reusable manufacturing system that can deliver various therapeutic molecules across different primary cell types, thus enhancing drug discovery and development processes.

XOMA Corporation is a biotechnology company focused on the discovery and development of therapeutic candidates, primarily in the fields of monoclonal antibodies and innovative drug technologies. With a robust pipeline, the company is developing proprietary product candidates such as X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody for Type 2 diabetes; and therapies targeting metastatic melanoma and renal cell carcinoma. XOMA also has initiatives aimed at addressing unmet medical needs related to hyperparathyroidism. In addition to its own product development, the company licenses antibody discovery and optimization technologies and collaborates with major pharmaceutical firms, including Novartis and Takeda, to enhance clinical development efforts. Founded in 1981 and headquartered in Emeryville, California, XOMA is positioned at the forefront of biopharmaceutical innovation, contributing to advancements in healthcare.

Dunad Therapeutics is a biopharmaceutical company dedicated to advancing next-generation therapies through targeted protein degradation. The company specializes in developing small molecule platforms designed to induce the degradation of disease-causing proteins, many of which are traditionally considered undruggable. This approach involves directly modulating protein stability and conformation, offering a novel molecular strategy that is both selective and applicable across various target classes. Unlike other technologies in this field, Dunad Therapeutics' method employs a unique mechanism of action, providing a distinct advantage in the development of targeted oral therapies.

Capstan Therapeutics is a biotechnology company focused on advancing precision in vivo cell engineering to create therapeutics for various disease categories that have unmet or underserved clinical needs. The company specializes in expanding the therapeutic potential of RNA-based therapies through proprietary targeted delivery systems. Their platform utilizes targeted lipid nanoparticles to enhance off-the-shelf immunotherapies, providing tight control over dosage and activity of engineered cells. This approach aims to develop transformative products for conditions such as oncology, fibrosis, and inflammation-related diseases.

Lightship is a company founded in 2018 that focuses on transforming clinical trials to enhance health equity globally. By leveraging digital health innovations and remote care, it aims to make clinical research more accessible and patient-centered. Lightship provides decentralized and hybrid clinical services that improve patient experience, retention, and trial diversity. Its approach expands the pool of potential participants by moving beyond traditional research centers, effectively meeting patients in their own environments. This strategy helps to eliminate the barriers and inefficiencies associated with conventional clinical trial models, ultimately making medical research more inclusive and effective.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing challenging pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to create a pipeline of drug candidates that target exosites, which are unique and distal binding pockets on enzymes. This innovative approach aims to reprogram enzyme activity, leading to precise and effective therapeutic outcomes, particularly in oncology and inflammation, while also minimizing potential side effects for patients. Exo Therapeutics is committed to unlocking breakthrough therapeutics through its team of experienced researchers and a deep understanding of complex disease mechanisms.

Expansion Therapeutics is a drug discovery and development company focused on creating small molecule medicines for RNA-mediated diseases. The company specializes in developing novel RNA-targeted drug candidates that aim to address a wide range of severe medical conditions. By leveraging its innovative technology, Expansion Therapeutics seeks to provide transformative oral treatment options, enhancing the therapeutic landscape for patients suffering from these complex diseases.

Arctos Medical, spun off from the University of Bern, focuses on developing innovative optogenetic therapies for treating genetic eye diseases leading to blindness. Their primary aim is to create accessible treatments for inherited retinal dystrophies (IRDs), enabling patients to potentially regain vision and improve their overall visual experience.

Flywheel.io is a cloud-based data management platform tailored for biomedical research and collaboration. Founded in 2012 and headquartered in Minneapolis, Minnesota, the company provides a suite of tools designed to enhance the workflow of scientists and researchers. Its platform supports medical imaging, scientific computation, and content management, enabling users to capture, manage, and analyze research data efficiently. By utilizing cloud scalability and automation, Flywheel facilitates collaborative research, machine learning applications, and multicenter studies, which help organizations streamline their research processes. The platform, featuring a modern web interface and extensible compute engine, aims to eliminate bottlenecks in innovation, allowing researchers to focus on scientific discovery rather than IT challenges.

Immunitas Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing targeted therapeutics for patients with complex cancers. Founded in 2019, the company utilizes a single-cell sequencing platform to analyze the biology of immune cells within human tumors. This innovative approach allows Immunitas to identify novel drug targets and develop key biomarkers that guide patient selection for their therapies. By emphasizing research rooted in human biology, Immunitas aims to bridge the gap between laboratory discoveries and clinical applications. The company is advancing multiple programs toward early human studies, leveraging its expertise in antibody discovery and engineering to create effective treatments that modulate identified targets.

GentiBio, Inc. is a biotherapeutics company that specializes in developing engineered regulatory T cells, known as EngTregs, aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, Washington, GentiBio employs a proprietary platform that combines autologous and allogeneic technologies. This platform enhances the ability to restore immune tolerance and addresses significant limitations found in existing regulatory T-cell therapeutics. By focusing on the underlying mechanisms of immune system disorders, GentiBio aims to provide innovative therapeutic solutions that tackle the root causes of diseases caused by dysregulated immune responses. The company is co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of advanced immunotherapy development.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

NuvoAir AB, established in 2015 and headquartered in Stockholm, Sweden, specializes in remote patient monitoring for chronic heart and lung conditions. The company's core product is Air Next, a home spirometer that tracks lung function. NuvoAir's innovative platform combines this advanced monitoring technology with personalized care from a multidisciplinary team, including pulmonologists and cardiologists. By collaborating with health plans and risk-bearing entities, NuvoAir offers a value-based care model that aims to reduce healthcare costs and improve patient outcomes.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Cellerys, headquartered in Zurich, Switzerland, is a biotechnology company focused on developing a novel therapy for multiple sclerosis (MS). The company's core business revolves around its proprietary therapeutic platform, which aims to induce immune tolerance in MS patients. This platform employs a semi-automated, good manufacturing practice process that combines autologous red blood cells with specific peptides. By doing so, Cellerys seeks to enable healthcare providers to treat MS through antigen-specific tolerance induction, potentially improving the care and outcomes for patients with autoimmune diseases.

Soteria Biotherapeutics, Inc. is a biotechnology company based in San Francisco, California, founded in 2018. The company focuses on developing innovative immunotherapies, specifically next-generation conditionally active bispecific T-cell engaging antibodies aimed at treating patients with solid tumors. Utilizing its proprietary T-LITE™ platform, Soteria creates bispecific antibody therapies that are activated by small molecules, allowing for safer and more effective treatments. This technology facilitates pulsatile activity, which reduces side effects and enables higher dosing, ultimately enhancing the therapeutic potential for cancer patients.

Oculis Holding AG is a global biopharmaceutical company focused on advancing eye care and preserving vision. The company has developed a novel drug delivery platform that enhances the absorption of therapeutics to both the anterior and posterior segments of the eye. This innovative approach enables the treatment of posterior eye diseases, such as diabetic macular edema, through a simple topical application, thus offering a non-invasive alternative to traditional methods. Oculis's product pipeline includes OCS-01, a topical treatment for diabetic macular edema; OCS-02, a topical biologic for dry eye disease; and OCS-05, a disease-modifying candidate targeting acute optic neuritis and other neuro-ophthalmic disorders, including glaucoma and diabetic retinopathy. Through its cutting-edge technologies and therapeutic candidates, Oculis aims to significantly improve patient outcomes in the field of ophthalmology.

Aktis Oncology is a biotechnology company focused on the discovery and development of a new class of targeted radiopharmaceuticals aimed at treating various solid tumor cancers. The company has developed proprietary platforms to create tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered for high tumor penetration and prolonged residence time, allowing for effective tumor elimination while reducing the side effects typically associated with cancer treatments. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing treatment precision and efficacy.

Amphista Therapeutics Limited is a biopharmaceutical company founded in 2017 and located in Motherwell, United Kingdom. It specializes in developing targeted protein degradation technology aimed at creating innovative cancer therapeutics. The company focuses on harnessing the body's natural processes to selectively degrade and eliminate disease-causing proteins. By advancing next-generation therapeutics, Amphista seeks to improve treatment efficacy for various diseases, particularly cancer, by modulating the abundance of proteins responsible for disease progression. This strategic approach aims to enhance patient outcomes and contribute to the advancement of therapeutic options in oncology.

Credence MedSystems, Inc. is a specialty pharmaceutical and drug delivery company based in Menlo Park, California. Established in 2011 and formerly known as SafeShot Technologies, the company focuses on developing innovative injectable drug delivery systems aimed at enhancing patient and caregiver safety. Its flagship products include the Companion Staked Needle Syringe, Companion Luer Syringe, and Companion Dual Chamber Reconstitution Safety Syringe, as well as the Epiphany Safety Syringe system, which features a vacuum-triggered, auto-retractable design for single-use applications. Credence MedSystems collaborates with SCHOTT AG to advance its technology, which emphasizes passive needle safety and reuse prevention, enabling a smoother commercialization process for pharmaceutical partners while minimizing risks associated with injection practices.

TScan Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing T cell receptor (TCR) engineered T cell therapies for cancer treatment. Its primary focus is on liquid tumors, with lead therapy candidates TSC-100 and TSC-101 aimed at addressing hematologic malignancies by targeting residual leukemia and preventing relapse following hematopoietic stem cell transplantation. In addition to its liquid tumor programs, TScan is advancing multiplexed TCR-T therapy candidates to tackle various solid tumors. The company employs a unique platform that identifies previously uncharacterized shared T cell antigens and assesses off-target TCR interactions, which supports the creation of TCR-T therapies with reduced off-target effects. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics aims to transform cancer treatment through innovative T cell therapies.

Aspen RxHealth is a Tampa, Florida-based company that provides an online platform designed to connect licensed pharmacists with patients requiring enhanced medication services. Through its app-based technology, Aspen RxHealth facilitates direct patient care by matching pharmacists with patients based on various social and clinical criteria, including language and medication regimens. The platform enables health plans and providers to efficiently link their patients to a community of pharmacists who can offer specialized clinical services, ranging from comprehensive medication reviews to targeted interventions. By optimizing communication and simplifying processes, Aspen RxHealth aims to improve patient outcomes and enhance the delivery of pharmaceutical care.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Cadent Therapeutics, Inc. is a precision neuroscience company focused on developing innovative therapies for serious neurological and psychiatric disorders. Founded in 2010 and based in Cambridge, Massachusetts, the company specializes in small molecule therapeutics that target NMDA receptors to address conditions such as depression, schizophrenia, Rett syndrome, and other cognitive and movement disorders. Cadent's approach combines target specificity, patient selection, and drug design to create allosteric modulators that can enhance neuronal firing regularity and restore brain rhythms. By leveraging novel quantitative endpoints, Cadent aims to develop first-in-class medications that improve cognitive and motor functions in patients, ultimately enhancing clinical outcomes for those suffering from various neurological diseases.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing challenging pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to create a pipeline of drug candidates that target exosites, which are unique and distal binding pockets on enzymes. This innovative approach aims to reprogram enzyme activity, leading to precise and effective therapeutic outcomes, particularly in oncology and inflammation, while also minimizing potential side effects for patients. Exo Therapeutics is committed to unlocking breakthrough therapeutics through its team of experienced researchers and a deep understanding of complex disease mechanisms.

Faze Medicines is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. It focuses on developing small molecule drugs targeting key drivers of disease pathology, with initial therapeutic areas including amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). The company employs advanced screening and proteomics techniques to define condensate interaction networks, aiming to pioneer innovative therapeutics based on biomolecular condensates. Through its research, Faze Medicines seeks to provide effective treatments for complex diseases such as ALS and frontotemporal dementia (FTD).

Pear Therapeutics, Inc. is a Boston-based commercial-stage healthcare company specializing in software-based digital therapeutics, also known as Prescription Digital Therapeutics (PDTs). Founded in 2013, the company develops clinically validated software solutions designed to treat a range of behavioral health disorders, including addiction, anxiety, depression, and chronic insomnia. Its suite of products includes mobile digital therapies that reward patients for engagement, and specific tools like reSET and reSET-O, aimed at treating substance use disorders. The company also offers Somryst, which provides neurobehavioral interventions for insomnia, and operates PearConnect, a patient services center that connects patients with advocates and resources, ensuring support throughout their treatment journey. Pear Therapeutics aims to enhance treatment outcomes by integrating digital therapies with pharmaceuticals and providing comprehensive support for patients, clinicians, and payors.

Mekonos Inc. is a biotechnology company founded in 2017 and based in San Francisco, California, specializing in the design, development, and production of gene and cell therapies. The company has created a proprietary cell-engineering platform that utilizes a silicon chip automated architecture to advance the field of genome editing. This innovative system-on-a-chip technology allows for the precise control of individual nanoneedles to inject single cells in a parallel architecture, enabling the industrial-scale production of engineered therapies for a range of genetic diseases, including cancers. Mekonos aims to provide healthcare providers with a reliable and reusable manufacturing system that can deliver various therapeutic molecules across different primary cell types, thus enhancing drug discovery and development processes.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.

Molecular Partners is a clinical-stage biopharmaceutical company dedicated to advancing modern medicine through the development of innovative therapies. The company specializes in a novel class of small protein therapeutics known as DARPin therapeutics, which are designed to target serious diseases, including cancer and sight-threatening disorders. Molecular Partners' product pipeline is organized into three primary areas: ophthalmology, focusing on therapies for retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, which includes DARPin candidates that feature unique mechanisms of action; and additional therapeutic areas. The firm's commitment to developing potent and versatile treatments positions it at the forefront of biopharmaceutical innovation.

Rappta Therapeutics Oy is a biopharmaceutical company focused on developing innovative anti-cancer drugs that target protein phosphatase 2A (PP2A), an essential enzyme involved in regulating protein de-phosphorylation and tumor growth. Established in 2019 and headquartered in Helsinki, Finland, with an additional office in the United States, the company is in the lead-optimization stage, working to create a series of first-in-class molecules that aim to reactivate this vital tumor suppressor. With proprietary development tools, Rappta Therapeutics is enhancing its capacity for rational drug design, thus providing therapeutic options for a variety of cancer types and certain important non-oncology conditions.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for genetically defined subpopulations affected by neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and sphingolipid storage disorders. ESCAPE Bio's pipeline includes innovative candidates like ESB1609, a small molecule S1P5 receptor agonist targeting CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor specifically designed for Parkinson's patients with the LRRK2 G2019S variant. Additionally, the company is developing a program aimed at addressing the needs of Alzheimer's patients who carry the ApoE4 risk allele. Through its precision-targeted approach, ESCAPE Bio seeks to provide effective treatment options for individuals with these complex genetic profiles.

Arkangel AI is a technology company that provides a no-code platform designed for healthcare organizations to harness the capabilities of artificial intelligence. Its platform enables the building, deployment, and management of machine learning algorithms at scale, focusing on the detection of preventable diseases. By generating detection results that are faster, more accurate, and cost-effective, Arkangel AI helps users identify the stage of health issues efficiently. The company's mission is to promote equitable health conditions globally, empowering individuals to live free from preventable diseases. Through its innovative solutions, Arkangel AI aims to enhance healthcare outcomes and accessibility for all.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Science 37, Inc. is a technology-enabled clinical trial company that specializes in developing patient-centric models for clinical research, aimed at accelerating biomedical discovery. The company utilizes its innovative platform, NORA (Network Oriented Research Assistant), a cloud-based mobile research tool that facilitates communication between researchers, patients, and mobile nurses through videos, surveys, and photographs. By providing decentralized clinical trial services, Science 37 enables access to diverse patient populations that traditional site-based research may overlook. The company has established itself as a leader in conducting virtual trials, leveraging an extensive network of telemedicine investigators and home-health nurses to enhance patient enrollment and retention. Serving a wide range of clients, including pharmaceutical sponsors, biotech firms, and academic institutions, Science 37 aims to transform clinical research through its comprehensive, fully integrated trial platform. Founded in 2014 and headquartered in Los Angeles, California, Science 37 continues to innovate in the field of clinical research.